Search results
Results from the WOW.Com Content Network
VRTX data by YCharts. With the biotech company's stock already posting impressive gains of over 9% in early 2025, it's worth examining whether Vertex stock remains a compelling buy right now.
Net income. US$3.62 billion (2023) Total assets: US$22.7 billion ... Vertex Pharmaceuticals Incorporated is an American biopharmaceutical company based in Boston, ...
Shares of Vertex Pharmaceuticals (NASDAQ: VRTX) are down about 9% from a peak the stock set in November, despite some highly positive news. The U.S. Food and Drug Administration (FDA) approved ...
VRTX Free Cash Flow Chart. VRTX Free Cash Flow data by YCharts. On top of this, Vertex has a huge amount of cash -- $14.6 billion at the end of the first quarter -- thanks to solid revenue growth ...
The following table lists the largest biotechnology and pharmaceutical companies ranked by market capitalization in billion US dollars. The change column indicates the company's relative position in this list compared to their relative position in the preceding year; i.e., an increase would be moving closer to rank 1 and vice versa.
Vertex Pharmaceuticals (NASDAQ: VRTX) fell by 13% on Dec. 19, when the rare-disease drug developer reported some lackluster results from a late-stage clinical trial. Vertex is best known for its ...
Reshma Kewalramani, is the president and chief executive officer of Vertex Pharmaceuticals, a biotechnology company based in Boston, Massachusetts, as of April 1, 2020. [1] [2] [3] She is the first female CEO of a large US biotech company. [2]
With Vertex Pharmaceuticals ... Is the stock worth buying? ... It didn't need anything like Ozempic to increase its trailing-12-month net income by nearly 102% during the past three years ...